Pharmaceuticals and Environment
Here you can find information about the environmental impact of pharmaceuticals. You can search for a substance name. The environmental risk refers to the use of a pharmaceutical. The knowledge support is based on three sources:
1. environmental information from the European Medicines Agency's (EMA's) European Public Assessment Reports (EPARs)
2. environmental information on Fass.se
3. environmental risk assessments for certain substances based on concentrations measured in the environment in Sweden and effect studies.
Based on the two first-mentioned sources, environmental information is missing for many medicinal products. The database is based on Region Stockholm's work in Sweden and may mean, for example, that information about the Wise list, the drug formulary of recommended essential medicines for the entire Stockholm healthcare region, has been included.
Information about the classification
In a document there is information about the classification of the environmental hazard and the environmental risk. The classification of the risk is usually based on theoretical calculations of the risk. For more information see Classification.
For some substances there is also a risk assessment made on the basis of concentrations measured in the environment in Sweden and efficacy studies with high quality. These assessments are presented in the documents for the substances and are made by independent ecotoxicological expertise. Continuous work is underway to provide more substance documents with this type of environmental information and also present comparisons of environmental risk between substances intended for the same indication. Based on this type of risk assessment, a table of environmentally hazardous drugs Pdf, 41 kB. was developed within the framework of Region Stockholm's environmental program 2017–2021.
Hartman E A R, van de Pol A C, Heltveit-Olsen S R, Lindbæk M, Høye S, Lithén S S et al. Effect of a multifaceted antibiotic stewardship intervention to improve antibiotic prescribing for suspected urinary tract infections in frail older adults (ImpresU): pragmatic cluster randomised controlled trial in four European countries BMJ 2023; 380 :e072319 doi:10.1136/bmj-2022-072319
Helle Håkonsen, Simone Dohle, Henric Rhedin, Tove Hedenrud. Preferences for medicines with different environmental impact – a Swedish population-based study. Environmental Advances (2023), doi: https://doi.org/10.1016/j.envadv.2023.10035
Helwig, K, Niemi, L, Stenuick, JY, et al. (2023), Broadening the perspective on reducing pharmaceutical residues in the environment. Environ Toxicol Chem. Accepted Author Manuscript. https://doi.org/10.1002/etc.5563
Blomstrand E, Kumar Rajasekharan A, Atefyekta S, Andersson M. Cross-linked lyotropic liquid crystal particles functionalized with antimicrobial peptides. International Journal of Pharmaceutics 627 (2022) 122215
Stepulane A, Kumar Rajasekharan A, and Andersson M. Multifunctional surface modification of PDMS for antibacterial contact killing and drug-delivery of polar, nonpolar, and amphiphilic drugs. ACS Appl. Bio Mater. 2022, 5, 5289−5301
Nada Hanna, Ashok J Tamhankar, Cecilia Stålsby Lundborg. Antibiotic concentrations and antibiotic resistance in aquatic environments of the WHO Western Pacific and South-East Asia regions: a systematic review and probabilistic environmental hazard assessment. Lancet Planet Health 2023; 7: e45–54.
Brandis G, Larsson J, Elf J. Antibiotic perseverance increases the risk of resistance development. PNAS 2023 Vol. 120 No. 2 e2216216120.